Figure 4

Bone formation and resorption parameters in LysM-Cre; Tak1^f/f mice.

(a) Calcein double labeling in femur of 2 month-old LysM-Cre; Tak1^f/f and control mice. The mice were injected with Calcein twice with an interval of 7 days. The mice were sacrificed 1 day after the second injection. The femur bones were embedded, sectioned and the images were taken using a Nikon microscope. (b) Calcein double labeling in the frontal bones of LysM-Cre; Tak1^f/f and control mice. (c) Calcein double labeling in the calvarial bones of 2 month-old LysM-Cre; Tak1^f/f and control mice. (d) Adult LysM-Cre; Tak1^f/f mice showed no change in bone formation rate (BFR). (e) Adult LysM-Cre; Tak1^f/f mice showed no change in mineral apposition rate (MAR). (f) Adult LysM-Cre; Tak1^f/f mice showed no change in the number of osteoblasts. (g) LysM-Cre; Tak1^f/f mice showed a decrease in urine DPD. The ELISA assays were performed on urine collected from mutant and control mice. N = 8. **p < 0.01 when the value of mutant mice was compared to that of control mice. (h) LysM-Cre; Tak1^f/f mice showed a normal level of serum Pi. (i) LysM-Cre; Tak1^f/f mice showed a normal level of serum Ca²⁺. (j) LysM-Cre; Tak1^f/f mice showed a decrease in the osteoclast surface per bone surface. N = 8. **p < 0.01 when the value of mutant mice was compared to that of control mice.